$441 Million is the total value of Abingworth LLP's 20 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 15.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCVX | Vaxcyte | $105,760,000 | +13.0% | 4,168,718 | 0.0% | 24.00% | -17.1% | |
| New | eFFECTOR | $67,027,000 | – | 4,822,114 | +100.0% | 15.21% | – | |
| New | Jasper | $58,030,000 | – | 5,628,558 | +100.0% | 13.17% | – | |
| VERA | Vera | $51,360,000 | +33.4% | 2,960,231 | 0.0% | 11.66% | -2.1% | |
| PHAT | Phathom | $38,512,000 | -5.4% | 1,203,135 | 0.0% | 8.74% | -30.6% | |
| SRRA | Buy | Sierra Oncology | $19,031,000 | +13.2% | 876,656 | +0.6% | 4.32% | -16.9% |
| RPHM | Buy | Reneo | $15,306,000 | -15.9% | 2,073,957 | +5.7% | 3.47% | -38.2% |
| SIEN | Sell | Sientra | $13,465,000 | -29.2% | 2,349,827 | -1.7% | 3.06% | -48.1% |
| VRNA | Veronasponds adr | $13,393,000 | -16.3% | 2,457,499 | 0.0% | 3.04% | -38.5% | |
| ACET | Adicet | $12,648,000 | -23.7% | 1,615,385 | 0.0% | 2.87% | -44.0% | |
| Spruce Bio | $10,719,000 | -46.6% | 1,792,518 | 0.0% | 2.43% | -60.8% | ||
| SLNO | Soleno | $9,500,000 | -18.4% | 10,302,602 | 0.0% | 2.16% | -40.1% | |
| NCNA | Nucanaadr | $8,567,000 | -6.9% | 3,333,333 | 0.0% | 1.94% | -31.6% | |
| XCUR | Exicure | $8,233,000 | -20.8% | 6,977,000 | 0.0% | 1.87% | -41.9% | |
| PRTK | Paratek | $5,060,000 | -28.6% | 1,041,131 | 0.0% | 1.15% | -47.6% | |
| AGLE | Aeglea | $1,912,000 | +14.4% | 240,500 | 0.0% | 0.43% | -16.1% | |
| MTEM | Molecular Templates | $1,340,000 | -14.3% | 200,000 | 0.0% | 0.30% | -37.1% | |
| CBAY | Cymabay | $478,000 | -16.3% | 131,036 | 0.0% | 0.11% | -39.0% | |
| OBSV | Obseva | $274,000 | +3.0% | 87,999 | 0.0% | 0.06% | -24.4% | |
| HSGX | Ocugen | $51,000 | -10.5% | 7,111 | 0.0% | 0.01% | -33.3% | |
| XFOR | Exit | X4 Pharma | $0 | – | -229,885 | -100.0% | -0.46% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-03 |
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.